Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Open Offer Oversubcribed

1 Jul 2014 10:47

RNS Number : 0577L
ViaLogy PLC
01 July 2014
 



1 July 2014

ViaLogy Plc

(the "Company")

 

Open Offer Oversubcribed

 

On 13 June 2014, ViaLogy Plc issued a circular to shareholders detailing that the Company had:

 

· conditionally acquired the entire issued share capital of Premaitha Health Limited ("Premaitha"), a molecular diagnostic company employing next generation DNA analysis technology to develop molecular diagnostic products intended to have a major beneficial impact on human health (www.premaitha.com);

 

· raised £6.5 million (before expenses) by means of the Placing; and

 

· intended to raise up to a further £0.7 million by means of the Open Offer.

 

The result of the Open Offer, which closed for acceptances at 11.00 a.m. on 30 June 2011, resulted in valid acceptances, including excess applications, being received in respect of 11,256,554 Open Offer Shares, representing a total of approximately 167 per cent. of those Open Offer Shares available and, as such, the Open Offer has been oversubscribed.

 

All valid applications in respect of basic entitlements under the Open Offer have been met in full and a scaling back exercise on a pro-rata basis to the number of excess Open Offer Shares applied for by Qualifying Shareholders under the Excess Application Facility has been undertaken.

 

The Company is therefore pleased to announce that it has raised gross proceeds of £7.2 million, comprising £0.7 million through the Open Offer and £6.5 million through the Placing.

 

The Proposals are subject to the approval of shareholders at a General Meeting to be held at 11.00 a.m. on 3 July 2014 at the offices of Panmure Gordon (UK) Limited, One New Change, London EC4M 9AF.

 

Adam Reynolds, Executive Chairman, commented:

"We are delighted by the support shown by our shareholders through the Open Offer. The net proceeds from the Placing and Open Offer will be used primarily to develop and commercialise the IONA® Test. "

 

This announcement should be read in conjunction with the full text of the Admission Document dated 13 June 2014. Defined terms in this announcement have the same meaning as those in the Admission Document.

 

 

For further information please contact:

ViaLogy Plc

Mark Collingbourne

 

 

+44 1620 810 183

 

Cairn Financial Advisers LLP

Nomad

Liam Murray

Avi Robinson

 

 

 

+44 20 7148 7900

 

Panmure Gordon (UK) Limited

Broker

Robert Naylor

Freddy Crossley

 

+44 20 7886 2500

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCKFLBBZDFZBBQ
Date   Source Headline
6th Apr 20204:40 pmRNSSecond Price Monitoring Extn
6th Apr 20204:36 pmRNSPrice Monitoring Extension
27th Mar 20203:00 pmRNSIssue of Share Options
25th Mar 20207:00 amRNSContract manufacturing agreement for COVID-19 test
16th Mar 20204:41 pmRNSSecond Price Monitoring Extn
16th Mar 20204:36 pmRNSPrice Monitoring Extension
13th Mar 202011:51 amRNSHolding(s) in Company
10th Mar 20207:00 amRNSAcquisition of French distribution channel
17th Feb 20207:00 amRNSCE Marking Technical File submission
14th Feb 202011:00 amRNSMedilink Award win for Outstanding Achievement
14th Feb 20207:00 amRNSTGA approves DPYD for sale in Australia
5th Dec 201912:10 pmRNSThe Healthcare+ Expo Taiwan
2nd Dec 20197:00 amRNSHalf-year Report
29th Nov 201912:05 pmRNSBionow Double Award Win
28th Nov 20197:00 amRNSOpening of New Facilities and Corporate HQ
15th Nov 20197:00 amRNSPrivate Investor Presentation
12th Nov 201910:12 amRNSNotice of Results
6th Nov 20191:52 pmRNSCapital Markets Day
1st Nov 20197:00 amRNSDirector/PDMR Shareholding
31st Oct 20197:00 amRNSLaunch of Yourgene FlexT Analysis Software
30th Oct 20197:00 amRNSIssue of Share Options
15th Oct 20197:00 amRNSAmerican Society of Human Genetics Annual Meeting
14th Oct 20197:00 amRNSHalf year trading update
1st Oct 20197:00 amRNSPrivate Investor Presentation
26th Sep 20197:00 amRNSCE-IVD Certification renewal
18th Sep 20197:00 amRNSLaunch of DPYD chemotoxicity diagnostic assay
17th Sep 20195:50 pmRNSResult of AGM
17th Sep 20197:00 amRNSAGM Statement
20th Aug 20197:00 amRNSNotice of AGM
19th Aug 201910:35 amRNSChange of Registered Office
16th Aug 20193:49 pmRNSHolding(s) in Company
16th Aug 20199:06 amRNSDirectorate Change
12th Aug 20197:00 amRNSAmendment to Share Options
1st Aug 20197:00 amRNSDirector/PDMR Shareholding
29th Jul 20197:00 amRNSAppointment of Director
10th Jul 20197:00 amRNSFinal Results, Business Update and Director Change
27th Jun 20197:00 amRNSNotice of Results
24th Jun 20197:00 amRNSYourgene participates in key global conferences
3rd Jun 20197:01 amRNSDirector's dealing
3rd Jun 20197:00 amRNSIssue of Share Options
9th May 20194:07 pmRNSDirector's dealing
9th May 20197:00 amRNSDirectors' dealing & warrant extension
1st May 20198:05 amRNSTotal Voting Rights
26th Apr 20195:12 pmRNSHolding(s) in Company
26th Apr 20195:01 pmRNSHolding(s) in Company
25th Apr 20194:40 pmRNSCompletion of Acquisition
18th Apr 20197:00 amRNSResults of Placing and Subscription
17th Apr 20194:50 pmRNSAppointment of Sole Corporate Broker
17th Apr 20194:48 pmRNSProposed Acquisition, Placing & Subscription
8th Apr 20197:00 amRNSFull-year Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.